Durante W, Liao L, Peyton K J, Schafer A I
Houston VA Medical Center, Department of Medicine, Baylor College of Medicine, Tex 77030, USA.
Circ Res. 1998 Jul 27;83(2):217-23. doi: 10.1161/01.res.83.2.217.
Thrombin, a serine protease, is a potent mitogen for vascular smooth muscle cells (SMCs), but its mechanism of action is not known. Since L-ornithine is metabolized to growth-stimulatory polyamines, we examined whether thrombin regulates the transcellular transport and metabolism of L-ornithine by vascular SMCs. Treatment of SMCs with thrombin initially (0 to 2 hours) decreased L-ornithine uptake, whereas longer exposures (6 to 24 hours) progressively increased transport. Kinetic studies indicated that thrombin-induced inhibition was associated with a decrease in affinity for L-ornithine, whereas stimulation was mediated by an increase in transport capacity. Thrombin induced the expression of both cationic amino acid transporter (CAT)-1 and CAT-2 mRNA. Furthermore, thrombin stimulated L-ornithine metabolism by inducing ornithine decarboxylase (ODC) mRNA expression and activity. The stimulatory effect of thrombin on both L-ornithine transport and ODC activity was reversed by hirudin, a thrombin inhibitor, and was mimicked by a 14-amino acid thrombin receptor-activating peptide. Thrombin also markedly increased the capacity of SMCs to generate putrescine, a polyamine, from extracellular L-ornithine. The thrombin-mediated increase in putrescine production was reversed by N(G)-methyl-L-arginine, a competitive inhibitor of cationic amino acid transport, or by alpha-difluoromethylornithine (DFMO), an ODC inhibitor. DFMO also inhibited thrombin-induced SMC proliferation. These results demonstrate that thrombin stimulates polyamine synthesis by inducing CAT and ODC gene expression and that thrombin-stimulated SMC proliferation is dependent on polyamine formation. The ability of thrombin to upregulate L-ornithine transport and direct its metabolism to growth-stimulatory polyamines may contribute to postangioplasty restenosis and atherosclerotic lesion formation.
凝血酶是一种丝氨酸蛋白酶,是血管平滑肌细胞(SMC)的一种强效促有丝分裂原,但其作用机制尚不清楚。由于L-鸟氨酸可代谢为具有生长刺激作用的多胺,我们研究了凝血酶是否调节血管SMC对L-鸟氨酸的跨细胞转运和代谢。用凝血酶处理SMC最初(0至2小时)会降低L-鸟氨酸摄取,而较长时间暴露(6至24小时)则会逐渐增加转运。动力学研究表明,凝血酶诱导的抑制作用与对L-鸟氨酸亲和力的降低有关,而刺激作用是由转运能力的增加介导的。凝血酶诱导阳离子氨基酸转运体(CAT)-1和CAT-2 mRNA的表达。此外,凝血酶通过诱导鸟氨酸脱羧酶(ODC)mRNA表达和活性来刺激L-鸟氨酸代谢。凝血酶对L-鸟氨酸转运和ODC活性的刺激作用可被凝血酶抑制剂水蛭素逆转,并被一种14个氨基酸的凝血酶受体激活肽模拟。凝血酶还显著增加了SMC从细胞外L-鸟氨酸生成腐胺(一种多胺)的能力。凝血酶介导的腐胺生成增加可被阳离子氨基酸转运的竞争性抑制剂N(G)-甲基-L-精氨酸或ODC抑制剂α-二氟甲基鸟氨酸(DFMO)逆转。DFMO也抑制凝血酶诱导的SMC增殖。这些结果表明,凝血酶通过诱导CAT和ODC基因表达来刺激多胺合成,并且凝血酶刺激的SMC增殖依赖于多胺的形成。凝血酶上调L-鸟氨酸转运并将其代谢导向具有生长刺激作用的多胺的能力可能有助于血管成形术后再狭窄和动脉粥样硬化病变的形成。